Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GPY
|
|||
| Former ID |
DIB012619
|
|||
| Drug Name |
OMP-18R5
|
|||
| Synonyms |
Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Oncomed pharmaceuticals; Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Frizzled-7 receptor (FZD7) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| Hippo signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Melanogenesis | ||||
| HTLV-I infection | ||||
| Pathways in cancer | ||||
| Proteoglycans in cancer | ||||
| Basal cell carcinoma | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Cadherin signaling pathway | ||||
| Wnt signaling pathway | ||||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | |||
| Wnt signaling network | ||||
| Syndecan-4-mediated signaling events | ||||
| Reactome | Class B/2 (Secretin family receptors) | |||
| PCP/CE pathway | ||||
| WikiPathways | Wnt Signaling Pathway | |||
| Wnt Signaling Pathway and Pluripotency | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01345201) A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.